New drug targets Cancer's 'Extra DNA' in early trial
Disease control
Ongoing
This early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of certain genes (oncogene amplifications). The study aims to find the safest dose and see if BBI-3…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated May 16, 2026 23:50 UTC